Anti-Epidermal Growth Factor Receptor Treatment Strategies in Advanced Pancreatic Cancer: Success or Failure?

被引：5

作者：

Boeck, Stefan ^{[1
]}

Heinemann, Volker ^{[1
]}

机构：

[1] Univ Munich, Klinikum Grosshadern, D-8000 Munich, Germany

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 03期

关键词：

PHASE-III TRIAL; GEMCITABINE; CETUXIMAB; COMBINATION; ERLOTINIB;

D O I：

10.1200/JCO.2010.31.8733

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

收藏

页码：E70 / E71

页数：2

相关论文

共 10 条

[1]

Boeck SH, 2010, J CLIN ONCOL S, V28, p18s

[2]

Douillard J, 2010, J CLIN ONCOL S, V28, p267s

[3]

EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment [J].

Huang, Chin-Lun ;

Yang, Chih-Hsin ;

Yeh, Kun-Huei ;

Hu, Fu-Chang ;

Chen, Kuan-Yu ;

Shih, Jin-Yuan ;

Lin, Zhong-Zhe ;

Yu, Chong-Jen ;

Cheng, Ann-Lii ;

Yang, Pan-Chyr .

LUNG CANCER, 2009, 64 (03) :346-351

[4]

Association of Epidermal Growth Factor Receptor Polymorphism, Skin Toxicity, and Outcome in Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment [J].

Klinghammer, Konrad ;

Knoedler, Maren ;

Schmittel, Alexander ;

Budach, Volker ;

Keilholz, Ulrich ;

Tinhofer, Ingeborg .

CLINICAL CANCER RESEARCH, 2010, 16 (01) :304-310

[5]

Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study [J].

Kullmann, F. ;

Hollerbach, S. ;

Dollinger, M. M. ;

Harder, J. ;

Fuchs, M. ;

Messmann, H. ;

Trojan, J. ;

Gaebele, E. ;

Hinke, A. ;

Hollerbach, C. ;

Endlicher, E. .

BRITISH JOURNAL OF CANCER, 2009, 100 (07) :1032-1036

[6]

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group [J].

Moore, Malcolm J. ;

Goldstein, David ;

Hamm, John ;

Figer, Arie ;

Hecht, Joel R. ;

Gallinger, Steven ;

Au, Heather J. ;

Murawa, Pawel ;

Walde, David ;

Wolff, Robert A. ;

Campos, Daniel ;

Lim, Robert ;

Ding, Keyue ;

Clark, Gary ;

Voskoglou-Nomikos, Theodora ;

Ptasynski, Mieke ;

Parulekar, Wendy .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) :1960-1966

[7]

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group-Directed Intergroup Trial S0205 [J].

Philip, Philip A. ;

Benedetti, Jacqueline ;

Corless, Christopher L. ;

Wong, Ralph ;

O'Reilly, Eileen M. ;

Flynn, Patrick J. ;

Rowland, Kendrith M. ;

Atkins, James N. ;

Mirtsching, Barry C. ;

Rivkin, Saul E. ;

Khorana, Alok A. ;

Goldman, Bryan ;

Fenoglio-Preiser, Cecilia M. ;

Abbruzzese, James L. ;

Blanke, Charles D. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) :3605-3610

[8]

Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer [J].

Van Cutsem, Eric ;

Vervenne, Walter L. ;

Bennouna, Jaafar ;

Humblet, Yves ;

Gill, Sharlene ;

Van Laethem, Jean-Luc ;

Verslype, Chris ;

Scheithauer, Werner ;

Cosaert, Aijing Shang Jan ;

Moore, Malcolm J. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (13) :2231-2237

[9]

Verslype C, 2009, J CLIN ONCOL, V27

[10]

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial [J].

Xiong, HQ ;

Rosenberg, A ;

LoBuglio, A ;

Schmidt, W ;

Wolff, RA ;

Deutsch, J ;

Needle, M ;

Abbruzzese, JL .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2610-2616